EXAI Key Statistics, Chart & Performance
The current stock price of EXAI is 4.84 USD. In the past month the price decreased by -4.16%. In the past year, price decreased by -21.94%.
EXAI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to EXAI. When comparing the yearly performance of all stocks, EXAI is a bad performer in the overall market: 87.66% of all stocks are doing better.
EXAI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EXAI. While EXAI seems to be doing ok healthwise, there are quite some concerns on its profitability.
EXAI Financial Highlights
Over the last trailing twelve months EXAI reported a non-GAAP Earnings per Share(EPS) of -1.65. The EPS increased by 5.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.37% | ||
| ROE | -36.43% | ||
| Debt/Equity | 0.05 |
EXAI Forecast & Estimates
8 analysts have analysed EXAI and the average price target is 5.46 USD. This implies a price increase of 12.75% is expected in the next year compared to the current price of 4.84.
For the next year, analysts expect an EPS growth of 42.38% and a revenue growth 63.9% for EXAI
EXAI Ownership
EXAI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.94 | 383.08B | ||
| AMGN | AMGEN INC | 15.09 | 177.71B | ||
| GILD | GILEAD SCIENCES INC | 14.81 | 150.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.28 | 111.36B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.48 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.43 | 47.46B | ||
| INSM | INSMED INC | N/A | 33.97B | ||
| NTRA | NATERA INC | N/A | 33.17B | ||
| BIIB | BIOGEN INC | 10.07 | 24.73B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.83B | ||
| INCY | INCYTE CORP | 16.39 | 20.66B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 20.32B |
Related stock screener links
About EXAI
Company Profile
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The company went IPO on 2021-10-01. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
Company Info
EXSCIENTIA PLC
The Schrodinger Building, Oxford Science Park
Oxford OXFORDSHIRE GB
Employees: 483
Phone: 441865818941
EXSCIENTIA PLC / EXAI FAQ
What does EXAI do?
Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company is headquartered in Oxford, Oxfordshire and currently employs 483 full-time employees. The company went IPO on 2021-10-01. The firm combines precision design with integrated experimentation to invent and develop drugs. The company uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. The company uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. The company has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. The company combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The firm's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.
What is the stock price of EXSCIENTIA PLC today?
The current stock price of EXAI is 4.84 USD. The price increased by 3.2% in the last trading session.
What is the dividend status of EXSCIENTIA PLC?
EXAI does not pay a dividend.
What is the ChartMill rating of EXSCIENTIA PLC stock?
EXAI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the employee count for EXAI stock?
EXSCIENTIA PLC (EXAI) currently has 483 employees.
Who owns EXSCIENTIA PLC?
You can find the ownership structure of EXSCIENTIA PLC (EXAI) on the Ownership tab.